CTEV
Claritev Corporation
CTEV offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over CTEV overall, supported by lower modeled downside and stronger fundamentals.
CTEV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Weak |
CTEV's revenue and profitability are currently stable, but its cash flow and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CTEV PE Valuation
CTEV has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CTEV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect CTEV's revenue to grow, with its earnings and profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CTEV on the outlook, with more favorable earnings and profitability expectations.
CTEV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$16.42 | +$4.87 |
| Q2 2026 | -$17.01 | +$24.30 |
| Q1 2026 | -$17.33 | +$55.77 |
| Q4 2025 | -$17.30 | +$84.62 |
| Q3 2025 | -$21.29 | +$73.36 |
| Q2 2025 | -$41.31 | +$30.69 |
| Q1 2025 | -$73.10 | -$34.30 |
| Q4 2024 | -$101.92 | -$96.32 |
CTEV is still losing money, but far less than before: $16.42 per share over the past year, against $101.92 at its worst in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CTEV on earnings quality, reporting a profit while its opponent remains loss making.
CTEV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $268.3M | +9.1% |
| Q2 2026 | $257.5M | +6.6% |
| Q1 2026 | $244.7M | +5.8% |
| Q4 2025 | $246.6M | +6.2% |
| Q3 2025 | $246M | +6.7% |
| Q2 2025 | $241.6M | +3.5% |
| Q1 2025 | $231.3M | -1.4% |
| Q4 2024 | $232.1M | -4.9% |
CTEV's revenue has grown year over year for six quarters in a row: $268M last quarter, up 9.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.7% | +3.6 points |
| Q2 2026 | 9.1% | +2.2 points |
| Q1 2026 | 2.7% | -1.5 points |
| Q4 2025 | -3.1% | +15 points |
| Q3 2025 | 4.1% | +151 points |
| Q2 2025 | 6.9% | +231 points |
| Q1 2025 | 4.2% | +212 points |
| Q4 2024 | -18% | -35 points |
CTEV has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CTEV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CTEV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.2M | -$9.9M |
| Q2 2026 | $54.6M | +49% |
| Q1 2026 | -$92.5M | -$23.6M |
| Q4 2025 | $36.4M | +$100.2M |
| Q3 2025 | -$16.3M | -140% |
| Q2 2025 | $36.6M | +$43.6M |
| Q1 2025 | -$68.9M | -459% |
| Q4 2024 | -$63.8M | -$60.2M |
CTEV's free cash flow was −$28M over the past year, against −$113M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CTEV on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTEV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +10.3K shares |
| 1 year | +3% | +495K shares |
| 3 years | +5% | +814K shares |
| 5 years | +4% | +653K shares |
| Available history | +562% | +14.4M shares |
CTEV has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CTEV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 9.4x | High |
| Q2 2026 | 9.6x | High |
| Q1 2026 | 9.7x | High |
| Q4 2025 | 9.6x | High |
| Q3 2025 | 10.3x | High |
| Q2 2025 | 52.3x | High |
| Q1 2024 | 85.5x | High |
| Q4 2023 | 7.7x | High |
CTEV's net debt is about 9.4 years of its operating earnings (EBITDA), down from 10 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CTEV on leverage, with a lower net debt burden relative to earnings.
CTEV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.9 | Neutral |
| Stochastic | 21.6 | Neutral |
CTEV's weekly RSI is 49 (neutral) and its Stochastic is 22 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CTEV PE vs Healthcare Sector
| Metric | CTEV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTEV has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CTEV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.9 | 13% above |
| 20 week MA | $29.1 | 7.6% below |
| 50 week MA | $26.9 | 0.1% below |
| 100 week MA | $32.3 | 17% below |
| 200 week MA | $36.3 | 26% below |
CTEV has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 26% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CTEV on trend strength, trading above more of its moving averages.
CTEV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $388.8 | $357.2 | -8.1% |
| 2021 | $357.2 | $176.8 | -51% |
| 2022 | $176.8 | $47.6 | -73% |
| 2023 | $47.6 | $57.6 | +21% |
| 2024 | $57.6 | $17.5 | -70% |
| 2025 | $17.5 | $42.0 | +140% |
| 2026 YTD | $42.0 | $26.9 | -36% |
CTEV's yearly returns have swung widely, from +140% in 2025 to −73% in 2022. It's down 36% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CTEV on returns for 2026, with the stronger performance.